SPRY · ARS Pharmaceuticals, Inc.
$4.29
+0.22 (+5.41%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$405.75M
Shares
99.45M
Volume · Oct 5
1.62M
Avg daily vol (3M)
1.85M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.29
Open$4.13
Day$4.03–4.40
52W close$4.07–13.06
Avg vol 30d1.5M
Short int23.1M · 23.2% float · 15.5d
Short vol74%
Last earningsAug 13, 2026
DataDec 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 5 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$116.93M
Trailing 12 months
Net income (TTM)
−$215.43M
Trailing 12 months
Revenue growth YoY
+114.2%
Year over year
Operating margin
-185.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-48.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$47.17M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.0%
Year over year · more shares
Price change (1Y)
-60.4%
Trailing year
Short interest
23.2%
Latest settlement · 15.5 days to cover
AI Brief
Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26
TL;DR. New CEO outlined a pivot to targeted provider selling for neffy with a >40% 2H 2026 SG&A cut and a stated path to cash flow breakeven by end of 2027, while Q2 U.S. neffy revenue rose to $26.2 million with total market share doubling to 5% and field-targeted share at 8%; the CSU Phase 2b interim readout was pushed to Q1 2027.
Bullish
- + Unique neffy prescribers more than tripled year over year to over 16,000
- + Company guides to >40% reduction in cash SG&A in 2H 2026 and a path to cash flow breakeven by end of 2027
- + Salesforce expansion completed and new CCO appointed to drive targeted provider execution
Bearish
- − Cash position declined to $143.8M as cumulative losses and operating outflows continued
- − Heavy reliance on shifting prescriber habits is explicitly flagged as a slow, methodical process with no near-term spike expected
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−47%
below
Price vs 50-day avg
−18%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−24%
trailing
6-month return
−47%
trailing
YTD return
−63%
this year
Relative strength
−59%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow
Distributing
3 of 208 funds reported for Sep 30 · net -12.1K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
23.20% of float · ▼ -0.6% MoM · 15.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
208 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
−5%
Y/Y
EPS growth
−2275%
Y/Y
Free cash flow
$-171.2M
Balance sheet
$55.1M
net debt
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 13, 2026
Aggregate SG&A and R&D expenses
· second half of 2026
Initiated
$114M – $126M
Cash-based SG&A and R&D expenses
· second half of 2026
Initiated
$100M – $110M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−47%
Bearish
Price vs 50-day avg
−18%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow
Distributing
3 of 208 funds reported for Sep 30 · net -12.1K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
23.20% of float · ▼ -0.6% MoM · 15.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
208 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $4 · 2%
Range high $13
vs 200-day avg -47%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Market share among field-targeted accounts | 8% | Q2 2026 | — |
| Total U.S. epinephrine market share | 5% | Q2 2026 | — |
| U.S. net product revenue | $26.2M | Q2 2026 | +104.7% |
|
|
|||
| Unique prescribers | 16,000 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPRY
this stock
ARS Pharmaceuticals, Inc.
|
$405.75M | -63.2% | -5.5% | — | 23.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPRY | +3.9% | -23.7% | -47.3% | -0.5% | -63.2% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +2.7% | -24.3% | -58.9% | -2.1% | -76.8% |